Thomas M. Jahn
Impact in
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 19
- Chronic Lymphocytic Leukemia Research 19
-
- Lymphoma Diagnosis and Treatment 13
- Co-authors
- Steven Coutré (17 shared papers)Ian W. Flinn (16 shared papers)Richard R. Furman (14 shared papers)Nina D. Wagner‐Johnston (11 shared papers)Brian J. Lannutti (6 shared papers)Langdon L. Miller (7 shared papers)Daniel Li (3 shared papers)Jennifer R. Brown (5 shared papers)
- Journals
- Journal of Clinical Oncology (10 papers)Blood (8 papers)Annals of Oncology (1 paper)Cancer Research (1 paper)PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie (1 paper)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Thomas M. Jahn
22 papers receiving 731 citations
Hit Papers
Peers
Comparison fields: 5 of 46
- Genetics 636
- Pathology and Forensic Medicine 437
- Hematology 204
- Immunology 219
- Oncology 96
Countries citing papers authored by Thomas M. Jahn
This map shows the geographic impact of Thomas M. Jahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Jahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Jahn more than expected).
Fields of papers citing papers by Thomas M. Jahn
This network shows the impact of papers produced by Thomas M. Jahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Jahn. The network helps show where Thomas M. Jahn may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas M. Jahn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia Hit paper breakdown → | 2014 | 465 |
| 2 | 2013 | 37 | |
| 3 | 2013 | 31 | |
| 4 | 2012 | 30 | |
| 5 | 2011 | 28 | |
| 6 | 2012 | 21 | |
| 7 | 2013 | 17 | |
| 8 | 2013 | 17 | |
| 9 | 2014 | 13 | |
| 10 | 2012 | 13 | |
| 11 | 2014 | 10 | |
| 12 | 2015 | 8 | |
| 13 | 2014 | 8 | |
| 14 | 2014 | 8 | |
| 15 | 2011 | 8 | |
| 16 | 2002 | 7 | |
| 17 | 2022 | 7 | |
| 18 | 2014 | 4 | |
| 19 | 2014 | 4 | |
| 20 | 2024 | 3 |
About Thomas M. Jahn
Thomas M. Jahn is a scholar working on Genetics, Pathology and Forensic Medicine, Immunology, Public Health, Environmental and Occupational Health and Hematology, having authored 22 papers that have together received 743 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (13 papers), Immunodeficiency and Autoimmune Disorders (7 papers), Acute Lymphoblastic Leukemia research (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Advanced Breast Cancer Therapies (3 papers), CAR-T cell therapy research (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Genetics (636 citations), Pathology and Forensic Medicine (437 citations), Hematology (204 citations), Immunology (219 citations) and Oncology (96 citations). Thomas M. Jahn has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Steven Coutré, Ian W. Flinn, Richard R. Furman, Nina D. Wagner‐Johnston, Brian J. Lannutti, Langdon L. Miller, Daniel Li, Jennifer R. Brown, Sissy Peterman and Don M. Benson. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, Cancer Research and PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.